Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 136

1.

Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis.

Hazell PL, Kohn MR, Dickson R, Walton RJ, Granger RE, Wyk GW.

J Atten Disord. 2011 Nov;15(8):674-83. doi: 10.1177/1087054710379737. Epub 2010 Sep 13.

PMID:
20837981
[PubMed - indexed for MEDLINE]
2.

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.

Clin Ther. 2007 Jun;29(6):1168-77.

PMID:
17692731
[PubMed - indexed for MEDLINE]
3.

How oppositionality, inattention, and hyperactivity affect response to atomoxetine versus methylphenidate: a pooled meta-analysis.

van Wyk GW, Hazell PL, Kohn MR, Granger RE, Walton RJ.

J Atten Disord. 2012 May;16(4):314-24. doi: 10.1177/1087054710389989. Epub 2011 Feb 2.

PMID:
21289234
[PubMed - indexed for MEDLINE]
4.

[Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].

Purper-Ouakil D, Fourneret P, Wohl M, Rénéric JP.

Encephale. 2005 May-Jun;31(3):337-48. Review. French.

PMID:
16142049
[PubMed - indexed for MEDLINE]
5.

Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis.

Hanwella R, Senanayake M, de Silva V.

BMC Psychiatry. 2011 Nov 10;11:176. doi: 10.1186/1471-244X-11-176.

PMID:
22074258
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.

Wang Y, Zheng Y, Du Y, Song DH, Shin YJ, Cho SC, Kim BN, Ahn DH, Marquez-Caraveo ME, Gao H, Williams DW, Levine LR.

Aust N Z J Psychiatry. 2007 Mar;41(3):222-30.

PMID:
17464703
[PubMed - indexed for MEDLINE]
7.

Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.

Kratochvil CJ, Heiligenstein JH, Dittmann R, Spencer TJ, Biederman J, Wernicke J, Newcorn JH, Casat C, Milton D, Michelson D.

J Am Acad Child Adolesc Psychiatry. 2002 Jul;41(7):776-84.

PMID:
12108801
[PubMed - indexed for MEDLINE]
8.

Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study.

Kemner JE, Starr HL, Ciccone PE, Hooper-Wood CG, Crockett RS.

Adv Ther. 2005 Sep-Oct;22(5):498-512.

PMID:
16418159
[PubMed - indexed for MEDLINE]
9.

Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.

Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ.

Pediatrics. 2004 Jul;114(1):e1-8.

PMID:
15231966
[PubMed - indexed for MEDLINE]
10.

Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.

Niederkirchner K, Slawik L, Wermelskirchen D, Rettig K, Schäuble B.

Expert Rev Neurother. 2011 Apr;11(4):499-508. doi: 10.1586/ern.11.18.

PMID:
21469923
[PubMed - indexed for MEDLINE]
11.

Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial.

Wietecha L, Williams D, Shaywitz S, Shaywitz B, Hooper SR, Wigal SB, Dunn D, McBurnett K.

J Child Adolesc Psychopharmacol. 2013 Nov;23(9):605-13. doi: 10.1089/cap.2013.0054. Epub 2013 Nov 9.

PMID:
24206099
[PubMed - indexed for MEDLINE]
12.

Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.

[No authors listed]

Prescrire Int. 2010 Feb;19(105):5-8.

PMID:
20455329
[PubMed - indexed for MEDLINE]
13.

Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.

Schulz KP, Fan J, Bédard AC, Clerkin SM, Ivanov I, Tang CY, Halperin JM, Newcorn JH.

Arch Gen Psychiatry. 2012 Sep;69(9):952-61. doi: 10.1001/archgenpsychiatry.2011.2053.

PMID:
22945622
[PubMed - indexed for MEDLINE]
14.

Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo.

Buitelaar JK, Wilens TE, Zhang S, Ning Y, Feldman PD.

J Child Psychol Psychiatry. 2009 Mar;50(3):335-42. doi: 10.1111/j.1469-7610.2008.01960.x.

PMID:
19309330
[PubMed - indexed for MEDLINE]
15.

Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder.

Biederman J, Heiligenstein JH, Faries DE, Galil N, Dittmann R, Emslie GJ, Kratochvil CJ, Laws HF, Schuh KJ; Atomoxetine ADHD Study Group.

Pediatrics. 2002 Dec;110(6):e75.

PMID:
12456942
[PubMed - indexed for MEDLINE]
16.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
[PubMed - indexed for MEDLINE]
17.

Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.

Kaplan S, Heiligenstein J, West S, Busner J, Harder D, Dittmann R, Casat C, Wernicke JF.

J Atten Disord. 2004 Oct;8(2):45-52.

PMID:
15801334
[PubMed - indexed for MEDLINE]
18.

Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia.

Martenyi F, Zavadenko NN, Jarkova NB, Yarosh AA, Soldatenkova VO, Bardenstein LM, Kozlova IA, Neznanov NG, Maslova OI, Petrukhin AS, Sukchotina NK, Zykov VP.

Eur Child Adolesc Psychiatry. 2010 Jan;19(1):57-66. doi: 10.1007/s00787-009-0042-7. Epub 2009 Jul 1.

PMID:
19568826
[PubMed - indexed for MEDLINE]
19.
20.

Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis.

Cheng JY, Chen RY, Ko JS, Ng EM.

Psychopharmacology (Berl). 2007 Oct;194(2):197-209. Epub 2007 Jun 16.

PMID:
17572882
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk